-
Mashup Score: 0
The management of advanced prostate cancer (APC) has undergone some major changes in recent years from patient evaluation to treatment secondary to the addition of many new treatments to our toolbox by way of recent genetics and clinical trials. Although only 6% of our prostate cancer patients will initially present with distant disease, we know that the implications on quality of life and…
Source: www.auanet.orgCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0AUA 2021: AUA Guideline Amendment: Non-Muscle Invasive Bladder Cancer/Muscle Invasive Bladder Cancer - 2 year(s) ago
AUA 2021 AUA guidelines, guideline update for non-muscle invasive bladder cancer, AUA guidelines muscle invasive bladder cancer, high-grade T1 disease, SWOG S0337 trial, intravesical gemcitabine versus saline immediately following TURBT.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
AUA 2021 efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, primary chemoablative therapy in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Primary chemoablation of low-grade intermediate-risk non-muscle-invasive #BladderCancer using UGN-102, a mitomycin-containing reverse thermal gel #OPTIMAII. Presented by @UroWCH @nyulangone. #AUA21 written coverage by @WallisCJD @UofT > https://t.co/m5AIRlCcD6 @AmerUrological https://t.co/eIKf5HEL3L
-
-
Mashup Score: 0
AUA 2021 female patients in the OLYMPUS trial, the outcomes of female patients from the OLYMPUS trial, OLYMPUS trial, patients with LG-UTUC, reverse thermal gel containing mitomycin (UGN-101 – JELMYTO® (mitomycin) upper tract urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Female patients with low-grade UTUC: primary chemoablation and durability of response in a subgroup analysis from the #OLYMPUS trial. Presented by @Dr_Jen_Linehan @ProvCalifornia. #AUA21 written coverage by @tchandra_uromd @JEFFUrology > https://t.co/qIX2XqKkyN @AmerUrological https://t.co/XJQeUkADnR
-
-
Mashup Score: 2AUA 2021: Long-Term Recurrence Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma - 2 year(s) ago
AUA 2021 kidney-sparing benefits, UGN-101 (JELMYTO), The OLYMPUS trial, long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1AUA 2021: AUA Guideline Amendment: Non-Muscle Invasive Bladder Cancer/Muscle Invasive Bladder Cancer - 2 year(s) ago
AUA 2021 AUA guidelines, guideline update for non-muscle invasive bladder cancer, AUA guidelines muscle invasive bladder cancer, high-grade T1 disease, SWOG S0337 trial, intravesical gemcitabine versus saline immediately following TURBT.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1
AUA 2021 female patients in the OLYMPUS trial, the outcomes of female patients from the OLYMPUS trial, OLYMPUS trial, patients with LG-UTUC, reverse thermal gel containing mitomycin (UGN-101 – JELMYTO® (mitomycin) upper tract urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Female patients with low-grade UTUC: primary chemoablation and durability of response in a subgroup analysis from the #OLYMPUS trial. Presented by @Dr_Jen_Linehan @ProvCalifornia. #AUA21 written coverage by @tchandra_uromd @JEFFUrology > https://t.co/qIX2XqKkyN @AmerUrological https://t.co/q9WYAgY7wC
-
-
Mashup Score: 2AUA 2021: Long-Term Recurrence Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma - 2 year(s) ago
AUA 2021 kidney-sparing benefits, UGN-101 (JELMYTO), The OLYMPUS trial, long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
AUA 2021 efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, primary chemoablative therapy in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Primary chemoablation of low-grade intermediate-risk non-muscle-invasive #BladderCancer using UGN-102, a mitomycin-containing reverse thermal gel #OPTIMAII. Presented by @UroWCH @nyulangone. #AUA21 written coverage by @WallisCJD @UofT > https://t.co/m5AIRlCcD6 @AmerUrological https://t.co/zaG7lI91zB
-
-
Mashup Score: 2
AUA 2021 efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, primary chemoablative therapy in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Primary chemoablation of low-grade intermediate-risk non-muscle-invasive #BladderCancer using UGN-102, a mitomycin-containing reverse thermal gel #OPTIMAII. Presented by @UroWCH @nyulangone. #AUA21 written coverage by @WallisCJD @UofT > https://t.co/m5AIRlCcD6 @AmerUrological https://t.co/xIiTJiwG3d
-
#TBT: "#AUA21 COURSE: Advanced Prostate Cancer" 🔗 https://t.co/I0J5eL9fZG "We can make a meaningful impact on these patients’ overall health and maximize their quality of life." By: Rachel Hastings, MS, PA-C; Anne Calvaresi, DNP, CRNP, RNFA; and Jim Kovarik, MS, PA-C #Urology https://t.co/xtEb1dERfk